In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco
-
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
How Tech Enables Environmental Justice at EPA
The agency wants to eliminate bias and establish new tech standards to reduce greenhouse gas emissions.
39m listen -
Building Better Data Governance Across FDA
The agency is using emerging technology to tackle its data challenges.
19m listen -
Coast Guard Poised for Growth in Cyber
The service’s prevention policy chief discusses his priorities for combatting cyber incidents that could have global impacts.
23m listen -
How VA is Using Digital Services to Expand Care to Veterans
CIO Kurt DelBene says the the agency’s 2024 priorities included AI adoption, hiring and a better user experience for veterans.
30m listen